Elizabeth R Allen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5461746/publications.pdf

Version: 2024-02-01

21 papers	10,410 citations	567281 15 h-index	642732 23 g-index
28 all docs	28 docs citations	28 times ranked	17412 citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
4	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
5	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	27.8	840
6	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
7	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
8	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	6.0	121
9	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	11.3	118
10	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 2021, 12, 2893.	12.8	104
11	Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3101-10.	7.1	103
12	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology, 2020, 160, 223-232.	4.4	86
13	A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Reports, 2018, 25, 3750-3758.e4.	6.4	41
14	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	6.1	23
15	Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein. IScience, 2020, 23, 101669.	4.1	19
16	Development of persistent gastrointestinal S. aureus carriage in mice. Scientific Reports, 2017, 7, 12415.	3.3	7
17	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. Frontiers in Immunology, 2021, 12, 763912.	4.8	5
18	Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease. Vaccine, 2019, 37, 502-509.	3.8	3

#	Article	IF	Citations
19	MRI Based Localisation and Quantification of Abscesses following Experimental S. aureus Intravenous Challenge: Application to Vaccine Evaluation. PLoS ONE, 2016, 11, e0154705.	2.5	2
20	Risk factors for dermatitis in submariners during a submerged patrol: an observational cohort study. BMJ Open, 2016, 6, e010975.	1.9	1
21	Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination. Vaccine, 2019, 37, 494-501.	3.8	1